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Pre-treatment neutrophil-to-lymphocyte
ratio is associated with neutrophil and
T-cell infiltration and predicts clinical
outcome in patients with glioblastoma
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Abstract
Background: Markers of systemic inflammation are correlated with patient survival in various cancers. The
prognostic value of neutrophil-to-lymphocyte ratio (NLR) was compared with that of platelet-to-lymphocyte ratio
(PLR) in patients with glioblastoma. The association of NLR with neutrophil and T- cell infiltration was also explored.
Methods: A total of 152 patients with glioblastoma were retrospectively analyzed. Clinical information was
obtained from electronic medical records. Kaplan-Meier analysis and the Cox proportional hazards models were
used to examine the survival function of pre-treatment NLR and PLR in these glioblastoma patients. Neutrophil and
CD3+ T-cell infiltration was assessed by immunohistochemical staining of tissue microarray cores from
glioblastomas.
Results: Pre-treatment NLR levels were significantly correlated with overall survival (OS) in glioblastoma patients
(multivariate hazard ratio =1.050; 95 % confidence interval, 1.003–1.100; P = 0.037). Despite the correlation between
NLR and PLR (R = 0.509, P < 0.001), NLR was superior to PLR as a prognostic factor. High pre-treatment NLR (≥4
versus < 4) was significantly associated with high neutrophil infiltration and low CD3+ T-cell infiltration into tumors,
and predicted poor OS (mean, 10.6 vs. 17.9 months, P < 0.001).
Conclusions: Pre-treatment NLR is of prognostic significance independent of MGMT status and is superior to PLR
as a prognostic factor. Our results demonstrate a correlation between elevated peripheral blood NLR levels and
increased tumor neutrophil infiltration/decreased CD3+ T-cell infiltration.
Background
Glioblastoma is the most common malignant primary
brain tumor in adults [1]. Currently, the standard treat-
ment for glioblastoma patients is debulking surgery
combined with radiotherapy and temozolomide (TMZ)
chemotherapy [2]. Despite receiving the same treatment,
glioblastoma patients show significant variation in their
clinical outcomes because of the heterogeneity of the tu-
mors and multiple systemic factors [3]. Therefore, prog-
nostic markers that can guide individual adjuvant therapy
and follow-up schedule are urgently needed. Prognostic
markers in the peripheral blood are of considerable clin-
ical value because of their accessibility [4].
Tumor-infiltrating immune cells, including neutrophils
and lymphocytes, play an important role in glioblastoma
progression and prognosis [5–10], reflecting the signifi-
cance of local inflammatory factors. However, the
heterogeneity in the amounts and the spatial localization
of tumor-infiltrating immune cells, both between and
within the patients’ tumors, limits their clinical use as
prognostic markers [7, 11]. Recently, the prognostic
value of neutrophil-to-lymphocyte ratio (NLR) in periph-
eral blood, a marker of systemic inflammatory responses,
was identified in glioblastoma [12, 13] and in many
other types of cancer [14–16]. In patients with glioblast-
oma, NLR >4 is an independent prognostic indicator of
poor outcome [12, 13]. These results raise the question
* Correspondence: cmuwuanhua@aliyun.com
1Department of Neurosurgery, The First Hospital of China Medical University,
Nanjing Street 155, Heping District, Shenyang 110001, China
Full list of author information is available at the end of the article
© 2015 Han et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Han et al. BMC Cancer  (2015) 15:617 
DOI 10.1186/s12885-015-1629-7
of whether another inflammatory marker, the platelet-to-
lymphocyte ratio (PLR) [15, 17], also has prognostic
value in glioblastomas. Therefore, the influence of dy-
namic changes on the prognostic significance of NLR
should be further examined, and the correlation between
local and systemic inflammatory markers should be
explored. In addition, the potential effects of the mo-
lecular marker O-methylguanine-DNA methyltransfer-
ase (MGMT) on the prognostic role of NLR remain
unclear. In the present study, we retrospectively ana-
lyzed 152 patients with glioblastoma treated in our
neurosurgical center to evaluate the prognostic value
of NLR and PLR. The association of NLR with neutro-
phil and T-cell infiltration was also assessed.
Methods
Study population
Clinical samples and patient records corresponding to 217
consecutive patients diagnosed with glioblastoma at the
Neurosurgery Department of the First Hospital of China
Medical University between January 2010 and October
2014 were examined. Patients with other diseases, includ-
ing diabetes mellitus, metabolic syndrome [18, 19], heart
disease (acute coronary syndromes, rheumatic or con-
genital heart disease and cardiomyopathy), hypertension
[20–22], severe renal or hepatic dysfunction, other can-
cers, inflammatory diseases, previous history of infection
within 3 months and any medication usage related to in-
flammatory conditions that could significantly influence
NLR or survival or those lacking complete data were
excluded. Finally, 152 newly diagnosed patients were in-
cluded in the analysis. Patients underwent surgical re-
section by neurosurgeons, who used similar operational
techniques and principles. Tumor samples were imme-
diately snap-frozen in liquid nitrogen after resection.
One part of each sample was fixed with formalin, embed-
ded with paraffin wax and, kept at room temperature.
Glioblastomas were diagnosed by two neuropathologists
according to the World Health Organization 2007 criteria.
All patients received postoperative radio-chemotherapy
according to the Stupp protocol [2].
Overall survival (OS) was defined as the interval be-
tween surgery and death from glioblastoma. The median
follow-up period was 13 months (range, 1–53 months),
during which 123 (80.9 %) patients died from glioblast-
oma. Data were censored at the last follow-up for pa-
tients who were alive at the time of the analysis. The
present study was approved by the institutional review
board of The First Hospital of China Medical University,
and written informed consent was obtained from all gli-
oma tissue donors who consented to the use of the tumor
tissue and clinical data for future research. The research
was in compliance with the Helsinki Declaration.
Blood examination
Complete blood count was obtained preoperatively be-
fore any treatment (e.g., steroids) and repeated the first
day after surgery as previously described [23]. Blood
samples were tested by the staff at the Department of
Clinical Laboratory within 2 h of collection using a Sysmex
XE-2100 complete blood count analyzer (Sysmex, Kobe,
Japan). The analysis included blood neutrophil, lympho-
cyte and platelet counts. The normal reference range is
1.8–6.3 × 109/L for neutrophils, 1.1–3.2 × 109/L for lym-
phocytes, and 125–350 × 109/L for platelets. The NLR
was defined as the absolute neutrophil count divided by
the absolute lymphocyte count, and the PLR was de-
fined as the absolute platelet count divided by the abso-
lute lymphocyte count.
Tissue microarrays and immunohistochemistry
Tissue microarrays were constructed using 152 glio-
blastoma clinical samples and analyzed by immunohis-
tochemical staining as previously described [5, 24].
Samples were collected from the most phenotypically
representative tumor regions. Diluted primary anti-
bodies against human myeloperoxidase (MPO; ab134132,
1:250; Abcam, Cambridge, UK), CD15 (ab754, 1:50;
Abcam) or CD3 (ab16669, 1:100; Abcam) were used and
incubated overnight at 4 °C. Samples were then incubated
with the horseradish peroxidase labeled secondary anti-
body in the immunohistochemical kit (KIT-5930, MaxVi-
sion, Fu Zhou, China) for 30 min at room temperature.
Diaminobenzidine was used for color development and
hematoxylin as counterstain. Results were visualized and
photographed under a light microscope (Olympus BX-51;
Olympus Optical Co., Ltd., Tokyo, Japan).
Semi-quantitative evaluation was performed by exam-
ining each section using at least ten randomly selected
different high-power fields (HPF). Neutrophils and T-
cells were identified as cells staining positive for anti-
MPO and anti-CD3 antibodies, respectively, together
with their characteristic morphology. Neutrophils were
also verified by anti-CD15 staining. The number of infil-
trating neutrophils and T-cells was manually counted in-
dependently by two investigators (YL and ZL) and an
experienced neuropathologist (QL) blinded to the clinical
background of the patients. The mean number of neutro-
phils and T-cells per field was calculated. The following
scoring system was used: 0, <10 cells per field; 1, 10–20
cells per field; 2, 20–50 cells per field; 3, 50–100 cells per
field; 4, 100 or more cells per field [8]. When strong differ-
ences in scoring between observers occurred, the core was
re-evaluated to reach a concordant scoring [5].
MGMT promoter methylation status
Methylation-specific PCR (MSP) was performed as pre-
viously described [5, 25] to detect MGMT promoter
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methylation. Briefly, tissue samples were lysed with
490 μl lysis buffer containing 20 mM Tris-Cl (pH 8.0),
5 mM EDTA (pH 8.0), 400 mM NaCl and 1 % (w/v)
SDS, and digested with 10 μl proteinase K at 10 mg/ml
at 37 °C for 12 h. Genomic DNA was purified from the
lysate by phenol/chloroform extraction. One microgram
of DNA was denatured by NaOH and modified by so-
dium bisulfite. MSP was performed using primer se-
quences for MGMT as follows: 5′-TTT GTG TTT TGA
TGT TTG TAG GTT TTT GT-3′ (forward) and 5′-
AAC TCC ACA CTC TTC CAA AAA CAA AAC A-3′
(reverse) for the unmethylated reaction; and 5′-TTT
CGA CGT TCG TAG GTT TTC GC-3′ (forward) and
5′-GCA CTC TTC CGA AAA CGA AAC G-3′ (reverse)
for the methylated reaction. Each PCR reaction (10 μl)
was loaded onto nondenaturing 6 % polyacrylamide gels,
stained with ethidium bromide, and visualized under UV
illumination. The PCR reaction was repeated at least
three times.
Statistical analysis
Univariate and multivariate Cox proportional hazards
models were constructed. Sex, age, tumor size, pre-
treatment Karnofsky performance status (KPS), degree
of resection, body mass index (BMI), MGMT promoter
methylation, NLR, PLR, neutrophil count, platelet count
and lymphocyte count were included in the analysis. To
adjust for potential confounders, age, tumor size, KPS,
BMI, NLR, PLR, neutrophil count, platelet count and
lymphocyte count were used as continuous variables and
all of the other covariates were used as categorical vari-
ables. Tumor size was calculated based on preoperative
MRI scans as follows: longest diameter × widest diam-
eter × thickness (section thickness × the number of
layers) × 1/2. MGMT promoter methylation status was
dichotomized (methylation vs. unmethylation). Accord-
ing to previous reports [5, 26], tumor resection was de-
fined as follows: (0) biopsy or residual tumor >30 %, (1)
subtotal resection with residual tumor <30 %, and (2)
gross total resection. The NLR was also analyzed as a di-
chotomous variable, according to previous data where a
NLR ≥4 (versus NLR <4) conferred a worse prognosis
[12, 13]. Kaplan-Meier survival analysis was used to de-
termine the distribution of OS time, and the results were
analyzed with the log-rank test.
Pearson correlation analysis was used to examine the
correlation between clinical variables. The chi-square
test and ANOVA were used to determine statistical sig-
nificance. The Student’s t-test or Mann–Whitney U-test
was used for variables with parametric distribution or
non-parametric distribution, respectively. Statistical ana-
lyses were performed with SPSS 19.0 (SPSS Inc., Chicago,
IL, USA). A two-tailed P-value of <0.05 was regarded as
significant.
Results
Clinicopathologic data of the 152 glioblastoma patients
are summarized in Table 1; 106 (69.7 %) patients were
under and 46 (30.3 %) were over 60 years of age. The
KPS was 70–100 in 102 (67.1 %) patients and <70 in
50 (32.9 %) patients; 95 patients (62.5 %) were male.
The mean OS was 15.6 ± 11.2 months. The corre-
sponding 1- and 2-year survival rates were 56.6 and
22.4 %, respectively.
In the present study, the mean pre-treatment neutrophil,
platelet and lymphocyte counts were 5.9 ± 3.6 × 109/L
(range, 1.2–18.6 × 109/L), 222.7 ± 61.3 × 109/L (range,
113–413 × 109/L) and 1.8 ± 0.7 × 109/L (range, 0.7–4.6 ×
109/L), respectively. The mean pre-treatment NLR was 4.1
± 3.8 (median, 2.54; range, 0.7–20.6), and the pre-
treatment PLR was 135.0 ± 57.1 (median, 122.1; range,
46.6–311.5). As shown in Table 1, the pre-treatment NLR
did not vary significantly with sex, age, tumor size, KPS,
degree of resection, BMI and MGMT promoter methyla-
tion status.
Pre-treatment NLR and the survival of glioblastoma
patients
Next, we examined the survival function of pre-treatment
NLR in glioblastoma patients. Univariate and multivariate
Cox regression analyses showed that pre-treatment NLR
was an independent predictor of OS (multivariate hazard
ratio = 1.050, 95 % confidence interval 1.003–1.100,
P = 0.037, Table 2). As shown in Fig. 1a and b, Patients
with high NLR (≥4) had lower 1-year and 2-year survival
rates than those with low NLR (<4). The OS of patients
with high NLR (≥4) was also shorter than that of patients
with low NLR (<4; mean 10.6 vs. 17.9 months, P < 0.001;
Fig. 1c). When the median pre-treatment NLR (2.54) was
used as the cutoff point, similar results were obtained
(Fig. 1d).
Multivariate analysis showed that KPS and MGMT
promoter methylation were also independently associ-
ated with OS in glioblastoma (Table 2). In keeping with
prior literature and prognostic nomograms [27], vari-
ables including age (≤60 vs. >60) and KPS (≤70 vs. 80–
100) were also analyzed as categorical variables. As
shown in Tables 1 and 3, similar results were obtained.
We further examined the influence of pre-treatment
NLR on OS across strata of other potential predictors,
including age, KPS, degree of resection, and MGMT
promoter methylation status. Pre-treatment NLR was
an independent prognostic factor in all the subgroups
(Fig. 2a).
However, postoperative NLR was not associated with
patient outcome in glioblastoma (Table 2). After surgery,
NLR increased significantly (mean ± SD: pre-treatment
4.1 ± 3.8 vs. postoperative 7.0 ± 6.7, P < 0.001; Fig. 2b) be-
cause of the effect of treatment, and so did PLR (pre-
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treatment 135.0 ± 57.1 vs. postoperative 177.7 ± 123.9,
P < 0.001; Fig. 2c), which may affect their prognostic
value. Moreover, consistent with a previous study [12],
pre-treatment neutrophil count, lymphocyte count, and
platelet count were not independently correlated with pa-
tient survival (Table 2).
Pre-treatment NLR is superior to PLR as a prognostic
factor in glioblastoma
In the present study, we observed a significant correl-
ation between the two systemic inflammatory markers,
pre-treatment NLR and PLR (R = 0.509, P < 0.001; Table 1
and Fig. 3). In univariate analysis, both NLR and PLR
(univariate hazard ratio = 1.004, 95 % confidence interval
1.001–1.007, P = 0.013, Tables 2 and 3) were associated
with patient survival. However, in multivariate analysis,
the prognostic significance of PLR was markedly dimin-
ished (Tables 2 and 3).
Pre-treatment NLR and immune cell infiltration
Tissue microarrays were used to assess neutrophil and
T-cell infiltration using immunohistochemical staining
in 152 glioblastomas. To evaluate the association be-
tween pre-treatment NLR and immune cell infiltration,
we semi-quantified the infiltrating neutrophils and CD3+
T-cells. The level of neutrophil infiltration was signifi-
cantly positively correlated with pre-treatment NLR level
(NLR < 4 vs. NLR ≥ 4; P < 0.001), whereas CD3+ T-cell





No. % No. % No. %
Total No. of patients 152 100 103 67.8 49 32.2
Sex 0.823
Male 95 62.5 65 68.4 30 31.6
Female 57 37.5 38 66.7 19 33.3
Age, years 0.136
Mean ± SD 50.4 ± 15.4 49.2 ± 16.2 53.1 ± 13.1
≤ 60 112 73.7 80 71.4 32 28.6 0.118
> 60 40 26.3 23 57.5 17 42.5
Tumor size, cm3 0.920
Mean ± SD 60.6 ± 26.6 60.4 ± 26.1 61.0 ± 28.0
KPS 0.212
Mean ± SD 71.4 ± 14.2 70.4 ± 15.2 73.5 ± 11.6
≤ 70 78 51.3 54 69.2 24 30.8 0.731
80–100 74 48.7 49 66.2 25 33.8
Resection 0.659
Biopsy 38 25.0 28 73.7 10 26.3
Subtotal 39 25.7 26 66.7 13 33.3
Gross total 75 49.3 49 65.3 26 34.7
BMI, kg/m2 0.150
Mean ± SD 24.2 ± 3.2 23.9 ± 3.3 24.8 ± 3.1
MGMT promoter 0.975
Methylated 53 34.9 36 67.9 17 32.1
Unmethylated 99 65.1 67 67.7 32 32.3
Pre-treatment PLR <0.001
Mean ± SD 135.0 ± 57.1 111.4 ± 34.7 184.8 ± 62.9
OS, months <0.001
Mean ± SD 15.6 ± 11.2 17.9 ± 11.0 10.6 ± 9.8
The differences between patients with pre-treatment NLR <4 and ≥4 were compared. P value was calculated using chi-square test for categorical variables and
using Student’s t-test for continuous variables
BMI Body Mass Index, KPS Karnofsky Performance Scores, MGMT O(6)-methylguanine-DNA-methyltransferase, NLR Neutrophil to Lymphocyte Ratio, OS Overall
Survival, PLR Platelet to Lymphocyte Ratio
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infiltration level was negatively correlated with pre-
treatment NLR level (P = 0.006; Table 4). According to
previous data and our results, a number of neutrophils
≥10/200 × HPF [8, 9] and a number of CD3+ T-cells
≥20/400 × HPF [7, 11] were used as cutoff points to de-
fine a high infiltration group and a low infiltration
group. High neutrophil infiltration and low CD3+ T-cell
infiltration were more frequent in patients with pre-
treatment NLR ≥4 than in those with pre-treatment
NLR < 4 (69.4 vs. 36.9 %, P < 0.001 and 59.2 vs. 38.8 %,
P = 0.019, respectively (Fig. 4a-c).
Kaplan-Meier analysis showed that increased neutrophil
infiltration was correlated with shorter survival (log-rank,
P = 0.016) (Fig. 4d-e). However, no association between
CD3+ T-cell infiltration and OS was observed (log-rank
P = 0.304) (Fig. 4f ), which could be attributed to the
complexity of its components.
Discussion
The identification of prognostic factors is clinically sig-
nificant for glioblastoma patients and can guide clinical
treatment and studies [28]. Previous studies show a
strong linkage between inflammation and cancer [29,
30]. Meanwhile, inflammatory markers have been associ-
ated with patient prognosis in glioblastoma [5, 7]. As a
marker of systemic inflammation, pre-treatment NLR
has been recognized as a prognostic factor in glioblast-
omas [12, 13]. However, this prognostic effect should be
re-evaluated in the era of standard therapy [2], when
molecular markers such as MGMT promoter methylation
are taken into consideration [28, 31]. In the present study,
NLR levels did not correlate with MGMT promoter
methylation status, and the prognostic role of NLR was
not significantly modified by MGMT promoter methyla-
tion status, suggesting that these two prognostic factors
may influence clinical outcome via different pathways and
mechanisms (Tables 1, 2 and 3).
Although pre-treatment NLR was an independent pre-
dictor of clinical outcome in glioblastoma patients, post-
operative NLR had no prognostic value. Postoperatively,
the NRL as well as the PLR level increased significantly
(Fig. 2b-c), indicating that the stress of surgery had an
impact on systemic inflammation. Thus, postoperative
NLR cannot reflect the baseline impact of systemic in-
flammation on clinical outcome in glioblastoma patients.
Moreover, some diseases, such as cardiovascular diseases
and infection, or drug treatments might affect neutrophil
and lymphocyte counts; therefore, the ratio of these two
parameters might be changed [32]. To minimize potential
confounders, patients with such medical history were ex-
cluded from this study. In addition, the NLR was mea-
sured before any treatment, including steroids. Therefore,
our results may reflect the influence of basic systemic in-
flammation, possibly induced by the tumor, on the prog-
nosis. Consistent with a previous study, we established a
positive correlation between the two markers of systemic
inflammatory responses, NLR and PLR [15]. Nevertheless,
the prognostic value of NLR and PLR may vary among
different cancers. In esophageal cancer, PLR is a better
prognostic factor than NLR [15], whereas in endometrial
cancer, NLR is a better prognostic factor [33]. We showed
that pre-treatment NLR was superior to PLR as a prog-
nostic factor in patients with glioblastoma. However, the
underlying mechanism needs further research.
Table 2 Univariate and multivariate analyses of different prognostic parameters for overall survival of 152 glioblastoma patients
Variable Univariate Multivariate
P HR 95 % CI P HR 95 % CI
Sexa 0.704 0.930 0.641–1.351 - - -
Ageb 0.050 1.013 1.000–1.026 0.157 1.010 0.996–1.024
Tumor sizeb 0.559 0.998 0.991–1.005 - - -
KPSb 0.034 0.986 0.973–0.999 0.023 0.985 0.972–0.998
Resectiona 0.047 0.800 0.641–0.997 0.183 0.860 0.688–1.074
BMIb 0.206 1.033 0.982–1.086 - - -
MGMT promotera 0.011 0.605 0.411–0.890 0.041 0.659 0.442–0.984
Pretreatment PLRb 0.013 1.004 1.001–1.007 0.152 1.003 0.999–1.007
Postoperative NLRb 0.285 1.015 0.988–1.043 - - -
Pretreatment neutrophilsb 0.620 1.010 0.971–1.051 - - -
Pretreatment lymphocytesb 0.531 0.999 0.996–1.002 - - -
Pretreatment plateletsb 0.637 0.999 0.997–1.002 - - -
Pretreatment NLRb <0.001 1.078 1.038–1.119 0.037 1.050 1.003–1.100
BMI Body Mass Index, KPS Karnofsky Performance Scores, MGMT O(6)-methylguanine-DNA-methyltransferase, NLR Neutrophil to Lymphocyte Ratio, PLR Platelet to
Lymphocyte Ratio
acategorical variable; bcontinuous variable
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Fig. 1 Pre-treatment neutrophil-to-lymphocyte ratio (NLR) and prognosis. a, b Pre-treatment NLR levels and 1-year (a) and 2-year (b) survival
rates. c, d Kaplan-Meier survival curves stratified by pre-treatment NLR levels. Survival time was significantly shorter among patients with
NLR ≥4 (or >2.54) than among those with NLR <4 (or ≤2.54)
Table 3 Univariate and multivariate analyses of different prognostic parameters for overall survival of 152 glioblastoma patients
Variable Univariate Multivariate
P HR 95 % CI P HR 95 % CI
Age (≤60 vs. >60) 0.025 1.603 1.060–2.424 0.478 1.168 0.755–1.806
KPS (≤70 vs. 80–100) 0.032 0.670 0.465–0.966 0.045 0.794 0.633–0.995
Resection (biopsy vs. STR vs. GTR) 0.047 0.800 0.641–0.997 0.110 0.738 0.509–1.071
MGMT promoter (unmethylated vs. methylated) 0.011 0.605 0.411–0.890 0.041 0.660 0.443–0.983
Pretreatment PLR (<135 vs. >135) 0.039 1.463 1.020–2.097 0.918 1.023 0.668–1.565
Pretreatment NLR (<4 vs. ≥4) <0.001 2.139 1.464–3.125 0.002 2.068 1.304–3.277
GTR gross total resection, KPS Karnofsky Performance Scores, MGMT O(6)-methylguanine-DNA-methyltransferase, NLR Neutrophil to Lymphocyte Ratio, PLR Platelet
to Lymphocyte Ratio, STR subtotal resection
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Definitive reasons for the association between elevated
NLR and poor survival in cancer patients have not been
identified to date. In the present study, we showed that
high pre-treatment NLR (≥4 vs. < 4) was significantly as-
sociated with high neutrophil infiltration and low CD3+
T-cell infiltration into glioblastomas. Previous data show
that neutrophil infiltration plays an important role in
stimulating tumor growth, angiogenesis and metastasis
[34–36]. In gliomas, there is a positive correlation be-
tween tumor grade and the extent of neutrophil infiltra-
tion [9]. Liang et al. reported that increased recruitment
of neutrophils promotes glioma progression and treat-
ment resistance [8]. Blocking neutrophil infiltration has
been suggested for the treatment of glioblastoma [37].
Consistently, we found a correlation of increased neutro-
phil infiltration with shorter survival in glioblastoma pa-
tients (Fig. 4d-e). Furthermore, neutrophils may suppress
the immune function [38] by inhibiting the cytolytic activ-
ity of CD8+ T-cells and natural killer cells [39, 40], and
by enhancing the suppressive activities of CD4+ sup-
pressor T cells [41]. T-lymphocytes play an important
role in host defenses against tumors, as they inhibit the
proliferation and invasion of tumor cells via the induc-
tion of cytotoxic cell death and cytokine production [30,
42]. Moreover, Kmiecik et al. reported an association
between elevated CD3+ T-cell infiltration and prolonged
survival in glioblastoma patients [11]. We found a nega-
tive correlation between pre-treatment NLR level and
the number of infiltrating CD3+ T-cells; however, CD3+
T-cell infiltration was not associated with patient out-
come. The complexity of CD3+ T-cell subpopulations
may affect its prognostic significance. While tumor-
infiltrating effector T cells (cytotoxic and helper) may
correlate with a better survival, the association between
Fig. 2 Correlation between pre-treatment NLR and other clinical factors in glioblastoma patients. a Stratified analysis of pre-treatment NLR level
and overall mortality. Hazard ratios and 95 % confidence intervals in various strata are shown. b Relationship between pre-treatment NLR and
postoperative NLR. c Relationship between pre-treatment PLR and postoperative PLR. NLR and PLR were assessed as continuous variables
Fig. 3 Pre-treatment NLR levels were significantly correlated with pre-treatment PLR levels. NLR and PLR were assessed as continuous variables
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tumor-infiltrating regulatory T cells and patient outcome
remains unclear in glioblastoma [5, 7, 43, 44]. Our results
indicate that, for glioblastoma patients, there could be a
correlation and interaction between systemic and local
inflammation, which may influence clinical outcome. In
future studies, analysis of T-cell subsets would enable us
to better understand this underlying relationship, and
the molecular mechanism also needs to be explored.
The present study had several limitations. Firstly, the
retrospective design of the study may lead to bias.
Secondly, although a standard primary treatment regi-
men was applied, the post-progression salvage treat-
ments were heterogeneous, which may have affected
the survival analysis. Moreover, other unknown physio-
logical and pathophysiological factors potentially affecting
NLR may have influenced our analysis.
Conclusion
We showed that pre-treatment NLR was superior to
PLR as a predictor of clinical outcome in patients with
Table 4 Correlation between neutrophils and CD3+ T-cells infiltration and pre-treatment NLR in 152 Glioblastomas
Neutrophils infiltration (200 × HPF) CD3+ T-cells infiltration (400 × HPF)
NLR≥ 4 (n = 49) NLR < 4 (n = 103) P NLR ≥ 4 (n = 49) NLR < 4 (n = 103) P
0 (<10) 15 (30.6 %) 65 (63.1 %) <0.001 18 (36.7 %) 12 (11.7 %) 0.006
1 (10–20) 8 (16.3 %) 28 (27.2 %) 11 (22.5 %) 28 (27.2 %)
2 (20–50) 17 (34.7 %) 7 (6.8 %) 11 (22.5 %) 37 (35.9 %)
3 (50–100) 2 (4.1 %) 1 (1 %) 8 (16.3 %) 19 (18.4 %)
4 (>100) 7 (14.3 %) 2 (1.9 %) 1 (2.0 %) 7 (6.8 %)
Fig. 4 Correlation between pre-treatment NLR and immune cell infiltration in glioblastomas. a Representative immunohistochemical images of
neutrophil infiltration and CD3+ T-cell infiltration in glioblastoma patients with pre-treatment NLR ≥4 and NLR <4. b, c Pre-treatment NLR ≥4
(versus NLR <4) significantly correlated with high neutrophil infiltration (b) and low CD3+ T-cell infiltration (c). High neutrophil infiltration (number
of neutrophils ≥10/200 × HPF) and low CD3+ T-cell infiltration (number of CD3+ T-cells <20/400 × HPF) were more frequent in patients with
pre-treatment NLR ≥4 than in those with pre-treatment NLR < 4 (69.4 vs. 36.9 %, P < 0.001 and 59.2 vs. 38.8 %, P = 0.019, respectively). d-f Kaplan-Meier
plots of overall survival, stratified by different levels of neutrophil infiltration (D and E) or CD3+ T-cell infiltration (f). Scale bars, 50 μm
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glioblastoma. NLR is of prognostic significance independ-
ent of MGMT status. Our results demonstrate a correl-
ation between elevated peripheral blood NLR levels and
increased tumor neutrophil infiltration/decreased CD3+
T-cell infiltration. The association of NLR in the periph-
eral blood with immune cell infiltration in the tumor
microenvironment provides insight into the mechanism
by which NLR can predict prognosis.
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